Recap Hey guys! If you’re new here, I am running a 6 month long experiment to see if a Large Language Model (like ChatGPT) can be a skilled micro-cap portfolio manager. I give it real time data at the end of every trading day and it has full control over its assets. Also, once every week it gets to use Deep Research to completely reevaluate it’s account. Can ChatGPT carve out consistent alpha in the dangerous world of micro-cap stocks? Lets find out. Overview This was yet another staggering week for ChatGPT. Despite facing a downturn on Monday, the growth the following days was unstoppable. Investing profits from  Candel Therapeutics Inc. (CADL) into Actuate Therapeutics, Inc. (ACTU) was genius, capturing a 27.37% rise. It’s other stocks however, were unimpressive. Azitra Inc (AZTR) continued to bleed cash and Inspira Technologies (IINN) had a slight gain of 3%. Performance Graph Portfolio Review Portfolio Review To see the full report: Click Here Click Here Here was this week’s revaluation summary: Rationale & Conclusion Rationale & Conclusion This rebalance aggressively reallocates capital toward the highest-upside opportunities while exiting a clear laggard. The strategy effectively trims profits (Inspira), cuts dead-weight (Azitra), and seizes two timely, catalyst-driven trades. highest-upside opportunities New Additions: New Additions: Axogen (AXGN):Near-term binary FDA decision (~6 weeks) for Avance, backed by an already profitable-growth model. Potential for a fast spike if approved, with downside cushioned by ongoing revenue.Esperion (ESPR):Turnaround cardiovascular story with real revenue growth and multiple quarters of cash runway. Risk/reward skews positive — if profitability or strategic news hits, a double is plausible. Diversifies the portfolio beyond devices/rare diseases. Axogen (AXGN): Axogen (AXGN): Near-term binary FDA decision (~6 weeks) for Avance, backed by an already profitable-growth model. Potential for a fast spike if approved, with downside cushioned by ongoing revenue. Esperion (ESPR): Esperion (ESPR): Turnaround cardiovascular story with real revenue growth and multiple quarters of cash runway. Risk/reward skews positive — if profitability or strategic news hits, a double is plausible. Diversifies the portfolio beyond devices/rare diseases. Key Holdings Retained: Key Holdings Retained: Abeona (ABEO):De-risked biotech with FDA-approved product (ZEVASKYN) launching now. Cash-rich and positioned for alpha as sales come in.Inspira Technologies (IINN):Riding momentum from major contracts and Nasdaq compliance. Trimmed for profits, but strong catalysts remain — continued upside likely.Actuate Therapeutics (ACTU):High-risk/high-reward oncology play with excellent data and strong investor backing. Stop-loss protects downside; upside could be a multi-bagger. Abeona (ABEO): Abeona (ABEO): De-risked biotech with FDA-approved product (ZEVASKYN) launching now. Cash-rich and positioned for alpha as sales come in. Inspira Technologies (IINN): Inspira Technologies (IINN): Riding momentum from major contracts and Nasdaq compliance. Trimmed for profits, but strong catalysts remain — continued upside likely. Actuate Therapeutics (ACTU): Actuate Therapeutics (ACTU): High-risk/high-reward oncology play with excellent data and strong investor backing. Stop-loss protects downside; upside could be a multi-bagger. Risk & Strategy Notes: Risk & Strategy Notes: AZTR exited due to weak near-term outlook and high dilution risk.AXGN and ESPR added for event-driven setups (FDA approval, profitability inflection).Position sizing remains disciplined — no over-concentration, all trades are full-share and within cash means.Stop-losses enforced to protect downside; failed trades will self-limit risk. AZTR exited due to weak near-term outlook and high dilution risk. AZTR exited AXGN and ESPR added for event-driven setups (FDA approval, profitability inflection). AXGN and ESPR added Position sizing remains disciplined — no over-concentration, all trades are full-share and within cash means. Position sizing remains disciplined Stop-losses enforced to protect downside; failed trades will self-limit risk. Stop-losses enforced Final Thoughts: Final Thoughts: This reallocation sets the portfolio up for a high-alpha second half of 2025. We’re now concentrated in positions with: Clear upcoming catalystsPositive news flow or earnings momentumInstitutional or insider alignment Clear upcoming catalysts Positive news flow or earnings momentum Institutional or insider alignment The new mix reflects a focused, evidence-backed, and risk-aware approach — fully aligned with the project’s mission to see if LLM-guided portfolios can consistently generate alpha in volatile micro-cap territory. My Thoughts Edit: Because AXGN was way above $7, it decided to just put the capital into ESPR (for a position of 20 shares). I like the idea of finally cutting off Azitra (AZTR), however I think it’s mostly because the new chat wants to restructure. I am a worried that it will lose conviction with the new picks and won’t wait for the event-setups. Also, I fed it PnL data for all tickers and IINN doesn’t have profits? So I’m unsure where it got that idea, but I’ll tell it before I put in the trades. Can it maintain this level of growth? Subscribe and find out next week! GitHub Page and Email: GitHub Page and Email: To see past deep research reports and summaries: Click Here Click Here Have a question? Check out: Q&A Q&A If you’re curious about the code I’m using to automate results and graph, the GitHub page is: ChatGPT-Micro-Cap-Experiment ChatGPT-Micro-Cap-Experiment If you have any suggestions or advice, my Gmail is : nathanbsmith729@gmail.com nathanbsmith729@gmail.com Thanks for reading! Subscribe to get an update every week and support my work.

Can ChatGPT Outperform the Market? Week 4

About Author

Comments

TOPICS

THIS ARTICLE WAS FEATURED IN

Related Stories

Untitled Story

Can ChatGPT Outperform the Market? A Finance Nerd's Quest to Find Out

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Darwin's Hybrid Intelligence to Align AI & Human Goals for Startups & VCs

The Noonification: White Man (11/26/2022)

The Noonification: The Metaverse is a Sh*tshow (11/2/2022)

Can ChatGPT Outperform the Market? A Finance Nerd's Quest to Find Out

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Darwin's Hybrid Intelligence to Align AI & Human Goals for Startups & VCs

The Noonification: White Man (11/26/2022)

The Noonification: The Metaverse is a Sh*tshow (11/2/2022)

Light-Mode

Classic

Newspaper

Dark-Mode

Neon Noir

Minty

HN StartUps